<DOC>
	<DOC>NCT01497600</DOC>
	<brief_summary>This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the the dose-response of insulin detemir and insulin NPH in subjects with type 2 diabetes of various race and ethnicity.</brief_summary>
	<brief_title>Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin, beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Isophane Insulin, Human</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>Type 2 diabetes Insulin treatment with any insulin preparation/regimen for at least three months with or without combination with below or equal to 2 oral antidiabetic agents (OADs) Duration of diabetes at least 12 months Body Mass Index (BMI) below 33 kg/m^2 HbA1c maximum 10 % based on analysis from the central laboratory Current treatment with insulin above 1.2 U/kg/day Current treatment with drugs known to interfere with glucose metabolism other than OADs such as systemic corticosteroids, nonselective betablockers, and monoamino oxidase (MAO) inhibitors Blood donation of more than 500 mL within the last three months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>